An article in the New York Times (Jan 4, 2012) describes FDA plans to restrict use of cephalasporins in agriculture. These antibiotics are used to treat strep and bronchitis and by surgeons. But they are also used on animals, with the resultant meat consumption creating bacteria resistant to these antibiotics. Farmers may face higher costs but the greater good is served. How should the FDA balance these competing interests ? How much risk or evidence standard should be used to balance such supply chain impacts ?